1
|
Louault K, Bonneaud TL, Séveno C, Gomez-Bougie P, Nguyen F, Gautier F, Bourgeois N, Loussouarn D, Kerdraon O, Barillé-Nion S, Jézéquel P, Campone M, Amiot M, Juin PP, Souazé F. Interactions between cancer-associated fibroblasts and tumor cells promote MCL-1 dependency in estrogen receptor-positive breast cancers. Oncogene 2019; 38:3261-3273. [PMID: 30631150 PMCID: PMC6756023 DOI: 10.1038/s41388-018-0635-z] [Citation(s) in RCA: 41] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2018] [Revised: 11/22/2018] [Accepted: 11/23/2018] [Indexed: 12/24/2022]
Abstract
Selective inhibition of BCL-2 is expected to enhance therapeutic vulnerability in luminal estrogen receptor-positive breast cancers. We show here that the BCL-2 dependency of luminal tumor cells is nevertheless mitigated by breast cancer-associated fibroblasts (bCAFs) in a manner that defines MCL-1 as another critical therapeutic target. bCAFs favor MCL-1 expression and apoptotic resistance in luminal cancer cells in a IL-6 dependent manner while their own, robust, survival also relies on MCL-1. Studies based on ex vivo cultures of human luminal breast cancer tissues further argue that the contribution of stroma-derived signals to MCL-1 expression shapes BCL-2 dependency. Thus, MCL-1 inhibitors are beneficial for targeted apoptosis of breast tumor ecosystems, even in a subtype where MCL-1 dependency is not intrinsically driven by oncogenic pathways.
Collapse
Affiliation(s)
- K Louault
- CRCINA, Team 8, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,SIRIC ILIAD, Angers, Nantes, France
| | - T L Bonneaud
- CRCINA, Team 8, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,SIRIC ILIAD, Angers, Nantes, France
| | - C Séveno
- CRCINA, Team 8, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,SIRIC ILIAD, Angers, Nantes, France
| | - P Gomez-Bougie
- SIRIC ILIAD, Angers, Nantes, France.,CRCINA, Team 10, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - F Nguyen
- CRCINA, Team 8, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,ONIRIS, Nantes Atlantic College of Veterinary Medicine Food Science and Engineering, Animal Cancers, Nantes, France
| | - F Gautier
- CRCINA, Team 8, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,SIRIC ILIAD, Angers, Nantes, France.,ICO René Gauducheau, Saint Herblain, France
| | - N Bourgeois
- CRCINA, Team 8, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,SIRIC ILIAD, Angers, Nantes, France
| | - D Loussouarn
- Service d'Anatomie Pathologique, CHU Nantes, Nantes, France
| | - O Kerdraon
- SIRIC ILIAD, Angers, Nantes, France.,ICO René Gauducheau, Saint Herblain, France
| | - S Barillé-Nion
- CRCINA, Team 8, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,SIRIC ILIAD, Angers, Nantes, France
| | - P Jézéquel
- CRCINA, Team 8, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,SIRIC ILIAD, Angers, Nantes, France.,ICO René Gauducheau, Saint Herblain, France
| | - M Campone
- CRCINA, Team 8, INSERM, Université d'Angers, Université de Nantes, Nantes, France.,SIRIC ILIAD, Angers, Nantes, France.,ICO René Gauducheau, Saint Herblain, France
| | - M Amiot
- SIRIC ILIAD, Angers, Nantes, France.,CRCINA, Team 10, INSERM, Université d'Angers, Université de Nantes, Nantes, France
| | - P P Juin
- CRCINA, Team 8, INSERM, Université d'Angers, Université de Nantes, Nantes, France. .,SIRIC ILIAD, Angers, Nantes, France. .,ICO René Gauducheau, Saint Herblain, France. .,CNRS GDR3697 Micronit, Tours, France.
| | - F Souazé
- CRCINA, Team 8, INSERM, Université d'Angers, Université de Nantes, Nantes, France. .,SIRIC ILIAD, Angers, Nantes, France. .,CNRS GDR3697 Micronit, Tours, France.
| |
Collapse
|